Wuhan Thalys Med Tech Co Ltd Cash Flow Conversion Efficiency
Wuhan Thalys Med Tech Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Wuhan Thalys Med Tech Co Ltd (603716) has a cash flow conversion efficiency ratio of 0.052x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥54.57 Million ≈ $7.99 Million USD) by net assets (CN¥1.05 Billion ≈ $154.13 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Wuhan Thalys Med Tech Co Ltd (2011–2025)
Cash flow conversion efficiency of Wuhan Thalys Med Tech Co Ltd from 2011 to 2025. This chart illustrates how Wuhan Thalys Med Tech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 603716 stock price and chart for real-time trading data and today's change.
Wuhan Thalys Med Tech Co Ltd Cash Flow Conversion Ratio Explained
Wuhan Thalys Med Tech Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Wuhan Thalys Med Tech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Wuhan Thalys Med Tech Co Ltd ranked by their cash flow conversion efficiency. Also see Wuhan Thalys Med Tech Co Ltd (603716) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CoinShares PLC Ordinary Shares
NASDAQ:CSHR
|
0.000x |
|
Harson Trading China Co Ltd
SHG:603958
|
0.049x |
|
Satellogic V Inc
NASDAQ:SATL
|
-0.255x |
|
HeNan Splendor Science & Technology Co Ltd
SHE:002296
|
0.019x |
|
Sierra Bancorp
NASDAQ:BSRR
|
0.034x |
|
Hangzhou Zhengqiang Corporation Limited
SHE:301119
|
0.045x |
|
Northern Arc Capital Ltd
NSE:NORTHARC
|
-0.034x |
|
Zhejiang Wellsun Intelligent Tech
SHE:300882
|
0.112x |
Annual Cash Flow Conversion Efficiency for Wuhan Thalys Med Tech Co Ltd (2011–2025)
The table below shows the annual cash flow conversion efficiency of Wuhan Thalys Med Tech Co Ltd from 2011 to 2025. Review Wuhan Thalys Med Tech Co Ltd free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥904.49 Million ≈ $132.35 Million |
CN¥-37.75 Million ≈ $-5.52 Million |
-0.042x | -140.32% |
| 2024-12-31 | CN¥962.04 Million ≈ $140.78 Million |
CN¥99.60 Million ≈ $14.57 Million |
0.104x | +8.12% |
| 2023-12-31 | CN¥1.31 Billion ≈ $192.38 Million |
CN¥125.89 Million ≈ $18.42 Million |
0.096x | +409.71% |
| 2022-12-31 | CN¥1.50 Billion ≈ $219.05 Million |
CN¥28.12 Million ≈ $4.12 Million |
0.019x | +124.52% |
| 2021-12-31 | CN¥1.74 Billion ≈ $255.04 Million |
CN¥-133.52 Million ≈ $-19.54 Million |
-0.077x | -1488.68% |
| 2020-12-31 | CN¥1.80 Billion ≈ $263.77 Million |
CN¥9.94 Million ≈ $1.46 Million |
0.006x | -90.48% |
| 2019-12-31 | CN¥1.62 Billion ≈ $237.21 Million |
CN¥93.92 Million ≈ $13.74 Million |
0.058x | +247.56% |
| 2018-12-31 | CN¥1.63 Billion ≈ $237.88 Million |
CN¥-63.83 Million ≈ $-9.34 Million |
-0.039x | +37.69% |
| 2017-12-31 | CN¥1.00 Billion ≈ $146.88 Million |
CN¥-63.25 Million ≈ $-9.26 Million |
-0.063x | -218.21% |
| 2016-12-31 | CN¥859.29 Million ≈ $125.74 Million |
CN¥-17.02 Million ≈ $-2.49 Million |
-0.020x | -120.20% |
| 2015-12-31 | CN¥470.30 Million ≈ $68.82 Million |
CN¥46.11 Million ≈ $6.75 Million |
0.098x | +32.39% |
| 2014-12-31 | CN¥405.99 Million ≈ $59.41 Million |
CN¥30.07 Million ≈ $4.40 Million |
0.074x | -21.25% |
| 2013-12-31 | CN¥345.97 Million ≈ $50.63 Million |
CN¥32.54 Million ≈ $4.76 Million |
0.094x | +933.02% |
| 2012-12-31 | CN¥296.50 Million ≈ $43.39 Million |
CN¥2.70 Million ≈ $394.98K |
0.009x | +109.55% |
| 2011-12-31 | CN¥253.90 Million ≈ $37.15 Million |
CN¥-24.22 Million ≈ $-3.54 Million |
-0.095x | -- |
About Wuhan Thalys Med Tech Co Ltd
Thalys Medical Technology Group Corporation provides medical integrated operation and management services in China. It offers automated immunofluorescence analyzer; coagulation reagent; COVID-19 test kit; line blot1 fully automated immunoblotting instrument; and flow products. The company also provides automated coagulation analyzer; automated immunoassay system; automated biochemical analysis sy… Read more